Research programme: neuroprotective therapies - Endo Pharmaceuticals
Alternative Names: ADNF-9; AL-209; AL-309; AL-408; AL-508; SAL; SALLRSIPALatest Information Update: 27 Apr 2024
At a glance
- Originator Allon Therapeutics
- Developer Endo, Inc.
- Class Nerve growth factors; Neuropeptides
- Mechanism of Action Neuron stimulants; Tubulin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alzheimer's disease
Highest Development Phases
- No development reported Alzheimer's disease; Eye disorders; Fetal alcohol syndrome; Neurodegenerative disorders; Peripheral nervous system diseases
Most Recent Events
- 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in Canada
- 04 Nov 2017 No recent reports of development identified for preclinical development in Fetal-alcohol-syndrome in Canada